ENTASIS THERAPEUTICS, INC. Waltham, MA, USA
Direct-Acting Small Molecule Therapeutic
Entasis Therapeutics is developing a novel antibiotic class targeting the penicillin-binding proteins (PBPs), cell wall targets unique to bacteria. While beta-lactams kill bacteria by binding to PBPs, bacteria have evolved to produce beta-lactamases which inactivate these agents. Entasis’ non-beta-lactam PBP inhibitors are unaffected by all four classes of beta-lactamases while demonstrating remarkable antibacterial activity. The lead compound demonstrates potent in vitro and in vivo antibacterial activity against some of the toughest to treat Gram-negative pathogens, including multi-drug-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacteriaceae, and multi-drug-resistant Acinetobacter baumannii.
Current Development Stage: Pre-Clinical
CARB-X Investment: Initial investment of up to $3.8m with potential option payments up to $6.3m. Additional investment of up to $5.63m to complete IND-enabling studies.
Initial CARB-X Investment Date: October 1, 2017
Read their Spotlight on Science